Welcome to our dedicated page for Esperion Therapeutics news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a leading pharmaceutical company specializing in the development and commercialization of innovative, first-in-class, oral therapies aimed at lowering low-density lipoprotein cholesterol (LDL-C). The company's flagship product, ETC-1002, is a potent inhibitor of ATP citrate lyase, an enzyme integral to the cholesterol biosynthesis pathway. This pathway also includes HMG-CoA reductase, the enzyme targeted by statins.
Esperion has made significant progress with ETC-1002, completing Phase 1 and Phase 2 clinical trials, and is set to initiate Phase 3 trials. The company's product lineup includes NEXLETOL and NEXLIZET, both of which are oral, once-daily, non-statin medications designed to tackle elevated LDL-C levels. These drugs have recently received expanded FDA approval for cardiovascular risk reduction and are indicated for both primary and secondary prevention patients.
In recent news, Esperion announced that both NEXLETOL and NEXLIZET have received broad new label expansions. These labels now cover cardiovascular risk reduction and expanded LDL-C lowering, either alone or in combination with statins. This approval allows over 70 million patients to access these life-saving drugs, positioning them as the non-statin drugs of choice for cardiovascular risk management.
Esperion is also ramping up its marketing and promotional efforts, enhancing patient support programs, and working with payers to improve patient access. The company is committed to breaking barriers in cardiovascular care and continues to focus on underserved populations, including women and Hispanic/Latinx patients, as demonstrated by their recent CLEAR Outcomes trial.
The company's forward-looking strategy includes ongoing clinical development, financial management, and expansion into new markets. Esperion's dedication to transforming cardiovascular care is evident in its robust pipeline and strategic initiatives aimed at addressing critical unmet medical needs.
Esperion (NASDAQ: ESPR) announced the grant of 48,780 restricted stock units (RSUs) to 14 new employees on April 28, 2022. These RSUs are part of the 2017 Inducement Equity Incentive Plan, aimed at attracting individuals to the company. Each RSU will vest 25% after one year, with the remaining 75% vesting quarterly over three years, contingent on continued employment. This initiative underlines Esperion’s commitment to innovation in cholesterol management, particularly through its oral, once-daily non-statin LDL-cholesterol lowering drugs.
Esperion (NASDAQ: ESPR) has announced that its President and CEO, Sheldon Koenig, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022. The event is set to take place at 3:20 PM PT (6:20 PM ET) and will include both a presentation and individual meetings. Investors can access a live audio webcast through the company's website, with a replay available afterwards for 90 days. Esperion focuses on developing effective oral non-statin medications for cholesterol management, aiming to improve patient health outcomes.
Esperion (NASDAQ: ESPR) has appointed Stephen Rocamboli as a Class I director, filling a vacancy left by Dr. Mark McGovern’s retirement. Rocamboli, who has extensive experience in life sciences, is expected to enhance Esperion’s strategic direction as it commercializes its medicines and prepares for the upcoming CLEAR Outcomes trial readout in Q1 2023. CEO Sheldon Koenig expressed confidence in Rocamboli's contributions towards the commercialization of approved products and the development of new therapies.
Esperion (NASDAQ: ESPR) has announced the launch of the CLEAR ACS trial, aimed at evaluating the efficacy of NEXLIZET in reducing LDL-C in patients post-acute coronary syndrome (ACS). This 24-week study will recruit 500 patients, assessing the drug's safety and effectiveness in diverse, high-risk populations often underrepresented in clinical trials. The findings could significantly impact treatment protocols for LDL-C management. Key endpoints include changes in LDL-C levels and cardiovascular outcomes.
Esperion (NASDAQ: ESPR) plans to report its first-quarter 2022 financial results on May 3, 2022, before U.S. markets open. Following the announcement, management will discuss the results and business progress during a conference call at 8:00 a.m. ET. Interested parties can join the call by dialing (877) 831-3840 or (253) 237-1184, with an access code of 1489326. A live audio webcast will also be available on the Esperion website, along with a replay accessible two hours after the call.
Esperion has released positive pooled Phase 3 data demonstrating significant LDL-C reductions. Bempedoic acid monotherapy resulted in a 26.5% reduction versus placebo, while a fixed-dose combination of bempedoic acid and ezetimibe achieved a 39.2% reduction, both statistically significant (p<0.001). The study involved 427 participants, emphasizing lipid management for statin-intolerant patients. Ongoing trials like CLEAR Outcomes aim to enhance understanding of bempedoic acid’s efficacy. The findings suggest promise for patients unable to tolerate statins, marking a potential shift in cholesterol management strategies.
Esperion presented significant clinical analyses for NEXLETOL (bempedoic acid) at the ACC.22 conference, highlighting its efficacy in lowering LDL-C in patients with renal impairment and hypertension. The analyses, covering over 3,600 patients, demonstrated significant LDL-C reductions (p<0.0001) across various patient groups. NEXLETOL is the first oral, once-daily non-statin LDL-C-lowering medication approved by the FDA in nearly two decades, supporting its use for adults with established cardiovascular disease or heterozygous familial hypercholesterolemia who need additional LDL-C lowering.
Esperion (NASDAQ: ESPR) announced that President and CEO Sheldon Koenig will present at the 21st Annual Needham Healthcare Conference on April 12, 2022. The event will feature a virtual fireside chat and 1:1 meetings, starting at 9:30 a.m. ET. Interested parties can access live audio webcasts on the investor relations section of the Esperion website. Replays will be available for 90 days following the event. Esperion is focused on lipid management, developing innovative medicines to lower cholesterol.
Esperion (NASDAQ: ESPR) will have its Chief Medical Officer, Dr. JoAnne Foody, participate in a Cardiometabolic/NASH panel at the Cowen 42nd Annual Healthcare Conference on March 8, 2022. This event will include one-on-one investor meetings and will be held in a virtual format starting at 12:50 p.m. ET. Live webcasts will be available on the company's investor relations website, with replays archived for 90 days post-event. Esperion focuses on lipid management and aims to provide innovative treatments for cholesterol reduction.
Esperion reported a strong performance for Q4 2021, with U.S. net product revenue for NEXLETOL and NEXLIZET growing 12% sequentially to $12.2 million, a 200% increase for the full year. Prescriptions rose by 9%, reaching approximately 70,000 patients. The company strengthened its capital position with $209 million from equity financing, extending its cash runway to support the upcoming CLEAR Outcomes trial results.
Esperion anticipates significant operating expenses in 2022, with R&D expenses projected between $100 million to $110 million.
FAQ
What is the current stock price of Esperion Therapeutics (ESPR)?
What is the market cap of Esperion Therapeutics (ESPR)?
What is Esperion Therapeutics, Inc.?
What products does Esperion offer?
What recent achievements has Esperion made?
What is ETC-1002?
What is the significance of the CLEAR Outcomes trial?
Who can benefit from Esperion's medications?
What partnerships does Esperion have?
What are the common side effects of NEXLETOL and NEXLIZET?
How does Esperion support its patients?
What are Esperion's future plans?
